about
Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer developmentOvarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.A suite of Perl modules for handling microarray data.Preanalytic influence of sample handling on SELDI-TOF serum protein profiles.Serum peptide profiling using MALDI mass spectrometry: avoiding the pitfalls of coated magnetic beads using well-established ZipTip technology.Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle studyThree-dimensional in vitro cell biology models of ovarian and endometrial cancer.A well-characterised peak identification list of MALDI MS profile peaks for human blood serum.Ovarian cancer screening was feasible but did not decrease incidence of index cancer or mortality.Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer.Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer.Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers.Early detection of ovarian cancer in samples pre-diagnosis using CA125 and MALDI-MS peaks.Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort.Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection.Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS).In vitro three-dimensional modeling of fallopian tube secretory epithelial cells.Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies.Detection of tumour lymphovascular space invasion using dual cytokeratin and CD31 immunohistochemistry.Screening for ovarian cancer in women with varying levels of risk, using annual tests, results in high recall for repeat screening tests.Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening.Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples.Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal womenHistological confirmation of breast cancer registration and self-reporting in England and Wales: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening.Psychosocial Factors Associated With Withdrawal From the United Kingdom Collaborative Trial of Ovarian Cancer Screening After 1 Episode of Repeat Screening.Age related trends in the incidence of endometrial cancer in South East England 1962-1997.Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers.Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancerNew tumor markers: CA125 and beyond.Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal DatasetEarly detection of cancer in the general population: a blinded case-control study of p53 autoantibodies in colorectal cancer.Quality assurance and its impact on ovarian visualization rates in the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)Time to diagnosis of Type I or II invasive epithelial ovarian cancers: a multicentre observational study using patient questionnaire and primary care records.Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancerRecruitment to multicentre trials--lessons from UKCTOCS: descriptive studySerum oestrogen receptor alpha and beta bioactivity are independently associated with breast cancer: a proof of principle study.Hereditary non-polyposis colorectal cancer or Lynch syndrome: the gynaecological perspective.Validity of self-reported hysterectomy: a prospective cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples.Changing trends in reproductive/lifestyle factors in UK women: descriptive study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
P50
Q28509811-AB903E9A-5212-4CBF-92D4-50AFC3E7423AQ30724410-2FB8C44D-0EBD-4440-A9ED-9436DB157F46Q31150156-7054CB28-8638-46EE-BA60-6F6E8762D3C9Q33274039-50484C8C-E57E-4C72-95B9-2C7A4517F03CQ33300244-E815EF54-9B7B-4A10-8837-51ACC5831476Q33352027-6A198859-8CBA-4CD6-8F5C-A58CB4A293EEQ33409977-DB011915-210B-4341-B7AE-F7CE7AC207F5Q33656838-3566B133-AAD7-4D18-A1B6-B331F3F450CEQ33727281-CE132EA0-8582-494A-AC31-91A3EE1BE71BQ33762434-99E41967-0E56-43B7-9F97-3B396020C6F1Q33919065-BFD61591-D057-4B0C-8E7D-3BF37CFA4AA8Q34009859-CAB09F07-BE0B-4807-AE1D-B87D1AC81E22Q34075337-6EC38A0E-8E26-4976-A89A-F91DF996FF49Q34154138-B3852B3C-39D2-47F6-8340-F1CD71A6C6AAQ34275247-1B5B66B3-4F51-4750-8D13-54FDCBF253A8Q34641672-8E339DE2-54F0-4093-9756-BD46C0D887E5Q35000194-25E51C55-3DC8-4373-BD34-725E66F86619Q35309119-C135E259-46A8-4B19-98C7-92E16E589995Q35587096-35C20BEE-50DF-4161-AFC6-A8A21A556905Q35596203-ECB8C7EF-CF83-4D88-8C29-CB9466977362Q35721991-02E05B2C-D760-475B-9959-60F1365E2CB0Q35863163-34114496-F3C2-4CF7-8AA5-B02752B1EC9AQ35878943-E0316ED5-CDB2-412B-838E-A51185654632Q36072762-AA8A90D6-179D-497F-981A-B05392EE7CB5Q36091425-4D321E8D-944B-4F59-943E-EF7D5A4CA5A6Q36251375-D1B83E6C-4A5A-4F03-998A-1B45CB74888FQ36252676-E1383322-8FA4-43C6-8B95-C84A69232D2BQ36320253-4BE37236-CB4E-4EF5-93B1-9410258CD328Q36338802-BEAB1847-F778-4962-A3E7-1A4BAE5D2211Q36446886-18B3F90D-7939-4D76-B2E0-EC162259972BQ36557829-FC861933-B551-4785-A9A8-F5F2826C1A71Q36584440-BBAB92F8-41EE-4965-986B-01DADA02FF1EQ36866311-3073D7E2-C138-4B45-B90B-61ED6F61B4B0Q36896106-0C3E3EB7-2278-4AA2-850E-4F59E4B5C48DQ36973956-1E8DAEF2-2CDE-43E6-86E6-0DEADA653490Q37269668-24DCCD39-3B36-4A5E-AD2E-73A9B6FDEB3FQ37362926-3F9F9DD6-4926-461C-BD27-2236297B312AQ37612191-19364F45-E9B7-404C-9FF7-F02AA6C14111Q37655098-40F8E444-53B2-42AF-8B0E-02E95871CBB0Q37704116-4C409D8A-D241-4D91-8CF2-7F8388CC96CE
P50
description
researcher
@en
wetenschapper
@nl
name
Ian Jacobs
@en
Ian Jacobs
@nl
type
label
Ian Jacobs
@en
Ian Jacobs
@nl
altLabel
I. Jacobs
@en
Jacobs IJ
@en
prefLabel
Ian Jacobs
@en
Ian Jacobs
@nl
P106
P31
P496
0000-0002-5005-2672